CompletedNot Applicable

Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses

Brazil15 participantsStarted 2020-08-03

Plain-language summary

The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.

Who can participate

Age range45 Years – 60 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosis of stage II-III breast cancer * starting adjuvant chemotherapy Exclusion Criteria: * metastatic disease, * hypercholesterolemia, diabetes, * hypertension, * severe lymphedema, * organic disorders (renal failure, heart failure and chronic liver disease), * obesity (BMI\> 30) and, * who are under pharmacological treatment with statins, angiotensin-converting enzyme inhibitors, losartan potassium, beta blockers or antioxidants

What they're measuring

Muscle sympathetic nerve activity

Timeframe: 15-20 days after the end of AC regimen

Trial details

NCT IDNCT04568161

SponsorUniversity of Sao Paulo General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-09-03

View on ClinicalTrials.gov More Cardiotoxicity trials